Ignite Creation Date:
2025-12-24 @ 7:22 PM
Ignite Modification Date:
2026-01-04 @ 6:09 AM
Study NCT ID:
NCT04930003
Status:
COMPLETED
Last Update Posted:
2023-12-07
First Post:
2021-02-22
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Reactogenicity, Safety and Immunogenicity of QazCoVac-P COVID-19 Vaccine
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D000086382', 'term': 'COVID-19'}, {'id': 'D045169', 'term': 'Severe Acute Respiratory Syndrome'}], 'ancestors': [{'id': 'D011024', 'term': 'Pneumonia, Viral'}, {'id': 'D011014', 'term': 'Pneumonia'}, {'id': 'D012141', 'term': 'Respiratory Tract Infections'}, {'id': 'D007239', 'term': 'Infections'}, {'id': 'D014777', 'term': 'Virus Diseases'}, {'id': 'D018352', 'term': 'Coronavirus Infections'}, {'id': 'D003333', 'term': 'Coronaviridae Infections'}, {'id': 'D030341', 'term': 'Nidovirales Infections'}, {'id': 'D012327', 'term': 'RNA Virus Infections'}, {'id': 'D008171', 'term': 'Lung Diseases'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE1', 'PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'SINGLE', 'whoMasked': ['PARTICIPANT']}, 'primaryPurpose': 'PREVENTION', 'interventionModel': 'PARALLEL', 'interventionModelDescription': 'Assignment'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 244}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2021-06-15', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2023-12', 'completionDateStruct': {'date': '2021-12-15', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2023-12-06', 'studyFirstSubmitDate': '2021-02-22', 'studyFirstSubmitQcDate': '2021-06-15', 'lastUpdatePostDateStruct': {'date': '2023-12-07', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2021-06-18', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2021-12-15', 'type': 'ACTUAL'}}, 'outcomesModule': {'otherOutcomes': [{'measure': 'Cell-mediated immune profile', 'timeFrame': 'at days 0, 7, 21, 42', 'description': 'Cellular immunity will be assessed by reliable (more than 2 standard deviations from the mean pre-vaccination level) increases in post-vaccination level (%) of CD4 + and CD8 + T-cells.'}], 'primaryOutcomes': [{'measure': 'Frequency of adverse events up to seven days after immunization', 'timeFrame': 'Seven days after each immunization', 'description': 'Frequency of adverse reaction in the seven days following each immunization per age group'}, {'measure': 'Frequency of adverse events up to 21 days after immunization', 'timeFrame': '21 days after each immunization', 'description': 'Frequency of adverse reaction in the 21 days following each immunization per age group'}, {'measure': 'The proportion of volunteers with increased levels of the immune response of specific neutralizing antibody titers in ELISA following the vaccination, compared with a placebo', 'timeFrame': 'at days 0, 21, 27, 42, 90, 180', 'description': 'The proportion of volunteers with changed levels of the immune response of specific neutralizing antibody titers in ELISA greater than ≥ 4 times compared with a placebo.'}], 'secondaryOutcomes': [{'measure': 'Incidence of serious adverse events during the study', 'timeFrame': 'throughout the study, an average of 42 days', 'description': 'Incidence of serious adverse events during the study.'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['vaccine,', 'I/II phase,', 'safety,', 'immunogenicity,', 'QazCoVac-P'], 'conditions': ['Covid19', 'SARS-CoV Infection', 'Vaccine Adverse Reaction']}, 'descriptionModule': {'briefSummary': 'Randomized, Blind, Placebo-controlled Phase- I Study and Randomized, Open Phase Phase-II Study of QazCoVac-P - COVID-19 Subunit Vaccine in Healthy Adult Volunteers From 18 Years Old and Elder', 'detailedDescription': 'Purpose of the Phase-I clinical study Evaluation of the safety, acceptability and immunogenicity of QazCoVac-P - COVID-19 Subunit vaccine when administered twice in healthy volunteers aged 18-50 years.\n\nPurpose of the Phase-II clinical study Evaluation of the safety and immunogenicity of QazCoVac-P - COVID-19 Subunit vaccine with single and dual use in healthy volunteers aged 18 and above'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '100 Years', 'minimumAge': '18 Years', 'healthyVolunteers': True, 'eligibilityCriteria': "Inclusion Criteria:\n\n* Availability of signed and dated informed consent of the volunteer to\n* participate in the study\n* Healthy male and female volunteers aged 18-50 and 50 and above.\n* Ability and voluntary desire to independently keep records in the SelfObservation Diary, as well as to carry out all the repeated visits provided for in the study for control medical observation.\n* The voluntary desire of females to use methods of reliable contraception throughout the entire period of their participation in the study.\n* Negative results for IgM and IgG antibodies to SARS-CoV-2.\n* Absence of COVID-19 diagnosis in history.\n* Absence in the last 14 days of close contact with persons suspected of being infected with SARS-CoV-2, or persons whose diagnosis of COVID-19 has been confirmed with laboratory.\n* Negative test results for human immunodeficiency virus (HIV), hepatitis B and hepatitis C.\n* Negative PCR results for coronavirus SARS-CoV-2\n* According to the results of a chest x-ray, there is no pathological process in the lungs.\n\nExclusion Criteria:\n\n* Aggravated allergic history, drug intolerance, including hypersensitivity to any of the components of the study drug, as well as a history of serious adverse events during vaccine administration (such as allergic reactions, respiratory failure, angioedema, abdominal pain).\n* Acute illness with a fever (body temperature ≥37.1°C) at the time of screening/randomization.\n* Chronic alcohol and/or drug use in history.\n* Clinically significant deviations from normal values during laboratory and/or imaging at screening.\n* Women with a positive urine pregnancy test.\n* Simultaneous treatment with immunosuppressive drugs, including corticosteroids (2 weeks) 4 weeks prior to study drug administration.\n* Acute or chronic clinically significant lesions of the lungs, cardiovascular system, gastrointestinal tract, liver, blood system, skin, endocrine, neurological and psychiatric diseases or impaired renal function (asthma, diabetes, thyroid disease, arrhythmia, myocardial infarction, severe hypertension not controlled by drugs, etc.), identified based on medical history, physical examination or clinical laboratory tests that, according to the researcher, may affect the study result.\n* Disruption of platelets or other blood clotting disorders, which may cause contraindications to intramuscular administration.\n* Leukemia or neoplasm in history.\n* Persons with autoimmune diseases.\n* Volunteers who received antiviral drugs, immunoglobulin's or blood transfusions or any other investigational drug within 4 weeks prior to study drug administration;\n* Volunteers who received anti-inflammatory drugs 2 days before study drug\n* administration;\n* Participation in any other clinical research within the last 3 months;\n* Volunteers with a concern that they will not comply with the study requirements, or persons with severe physical or mental disabilities that may affect the completion of the study;\n* Negative PCR results for coronavirus SARS-CoV-2;\n* According to the results of a chest x-ray, there is no pathological process in the lungs;\n* Voluntary refusal to study;\n* Vulnerable Volunteers of research."}, 'identificationModule': {'nctId': 'NCT04930003', 'briefTitle': 'Reactogenicity, Safety and Immunogenicity of QazCoVac-P COVID-19 Vaccine', 'organization': {'class': 'OTHER_GOV', 'fullName': 'Research Institute for Biological Safety Problems'}, 'officialTitle': 'Randomized, Blind, Placebo-controlled Phase- I Study and Randomized, Open Phase Phase-II Study of QazCoVac-P - COVID-19 Subunit Vaccine in Healthy Adult Volunteers From 18 Years Old and Elder', 'orgStudyIdInfo': {'id': 'QAZCOVAC-P-I/II-01/2020'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Experimental: Phase 1 Adult-vaccine (A Sample, blind study)', 'description': 'Group 1 (phase 1): 22 volunteers aged 18-50 years who will be the QazCoVac-P - COVID-19 twice spaced 21 days apart, intramuscularly, at a dose of 0.5 ml', 'interventionNames': ['Biological: QazCoVac-P -COVID-19 Subunit Vaccine']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'Phase 1 Adult-Placebo (A Sample, blind study)', 'description': 'Group 2 (phase 1): 22 volunteers aged 18-50 years who will be the Placebo twice spaced 21 days apart, intramuscularly, at a dose of 0.5 ml', 'interventionNames': ['Other: Placebo']}, {'type': 'EXPERIMENTAL', 'label': 'Phase 2 Adult-Vaccine, twice vaccination (An Open study)', 'description': 'Group 3 (phase 2): 50 volunteers aged 18-50 years who will be the QazCoVac-P - COVID-19 twice spaced 21 days apart, intramuscularly, at a dose of 0.5 ml', 'interventionNames': ['Biological: QazCoVac-P -COVID-19 Subunit Vaccine']}, {'type': 'EXPERIMENTAL', 'label': 'Phase 2 Elderly-Vaccine, twice vaccination (An Open study)', 'description': 'Group 4 (phase 2): 50 volunteers from 50 years old and elder who will be the QazCoVac-P - COVID-19 twice spaced 21 days apart, intramuscularly, at a dose of 0.5 ml', 'interventionNames': ['Biological: QazCoVac-P -COVID-19 Subunit Vaccine']}, {'type': 'EXPERIMENTAL', 'label': 'Phase 2 Adult-Vaccine, single vaccination (An Open study)', 'description': 'Group 5 (phase 2): 50 volunteers aged 18-50 years who will be the QazCoVac-P - COVID-19 single vaccination, intramuscularly, at a dose of 0.5 ml', 'interventionNames': ['Biological: QazCoVac-P -COVID-19 Subunit Vaccine']}, {'type': 'EXPERIMENTAL', 'label': 'Phase 2 Elderly-Vaccine, single vaccination (An Open study)', 'description': 'Group 6 (phase 2): 50 volunteers from 50 years old and elder who will be the QazCoVac-P - COVID-19 single vaccination, intramuscularly, at a dose of 0.5 ml', 'interventionNames': ['Biological: QazCoVac-P -COVID-19 Subunit Vaccine']}], 'interventions': [{'name': 'QazCoVac-P -COVID-19 Subunit Vaccine', 'type': 'BIOLOGICAL', 'description': 'QazCoVac-P (Subunit) Vaccine manufactured by Research Institute for Biological Safety Problems Republic of Kazakhstan', 'armGroupLabels': ['Experimental: Phase 1 Adult-vaccine (A Sample, blind study)', 'Phase 2 Adult-Vaccine, single vaccination (An Open study)', 'Phase 2 Adult-Vaccine, twice vaccination (An Open study)', 'Phase 2 Elderly-Vaccine, single vaccination (An Open study)', 'Phase 2 Elderly-Vaccine, twice vaccination (An Open study)']}, {'name': 'Placebo', 'type': 'OTHER', 'description': 'The use of placebo: intramuscularly, twice, spaced 21 days apart, at a dose of 0.5 ml (22 volunteers)', 'armGroupLabels': ['Phase 1 Adult-Placebo (A Sample, blind study)']}]}, 'contactsLocationsModule': {'locations': [{'zip': '080409', 'city': 'Gvardeyskiy', 'state': 'Jambul', 'country': 'Kazakhstan', 'facility': 'Research Institute for Biological Safety Problems Committee of Science of the Ministry of Education and Science of the Republic of Kazakhstan', 'geoPoint': {'lat': 43.57984, 'lon': 75.21392}}], 'overallOfficials': [{'name': 'Kunsulu Zakarya, Ph.D.', 'role': 'STUDY_CHAIR', 'affiliation': 'Research Institute for Biological Safety Problems'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Research Institute for Biological Safety Problems', 'class': 'OTHER_GOV'}, 'responsibleParty': {'type': 'SPONSOR'}}}}